Semaglutide vs Liraglutide
Liraglutide is the first-generation GLP-1 receptor agonist — daily injection, ~13-hour half-life. Semaglutide is the second-generation version — weekly injection, ~7-day half-life, stronger magnitude on weight and HbA1c endpoints. The research question is rarely which to pick, it's why someone would still pick Liraglutide.
Semaglutide beats Liraglutide on every meaningful axis for modern research: half-life (~7 days vs ~13 hours), magnitude of effect, and dosing cadence. Liraglutide is the first-generation tool that Semaglutide was designed to improve on. There's rarely a protocol reason to choose Liraglutide today except supply-constraint scenarios.
Contender A
Semaglutide
Also: Sema
Long-acting GLP-1 receptor agonist — fatty-acid modification extends half-life to weekly dosing. Same receptor, same class, different kinetics.
- Half-life
- ~7 days
- Primary use
- Modern GLP-1 research
- Dose range
- 0.25 mg -> 2.4 mg weekly
- Cost tier
- $$ · Moderate sourcing cost
Contender B
Liraglutide
Also: Lira
First-generation GLP-1 receptor agonist — shorter fatty-acid chain, daily dosing, same receptor pharmacology as Semaglutide.
- Half-life
- ~13 hours
- Primary use
- Legacy GLP-1 research
- Dose range
- 0.6 mg -> 3.0 mg daily
- Cost tier
- $$ · Moderate sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | Sema | Lira | Edge |
|---|---|---|---|
Receptor target | GLP-1 | GLP-1 | Tie |
Half-life | ~7 days | ~13 hours | Sema |
Dosing cadence | Weekly | Daily | Sema |
Weight-change magnitude | ~15% in 68 weeks | ~8% in 56 weeks | Sema |
HbA1c reduction | ~1.8% | ~1.2% | Sema |
GI tolerability | Moderate ramp | Similar ramp, more daily exposure | Sema |
Pulsatile vs steady GLP-1 signaling | Steady (weekly) | Peak-and-trough (daily) | Sema |
Evidence maturity | Very mature | Most mature (earliest) | Lira |
Research-sourcing cost | Moderate | Similar | Tie |
Protocol simplicity | Simple (weekly) | Disciplined (daily) | Sema |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
Liraglutide was the first GLP-1 agonist to show meaningful weight-loss magnitude and it still has real use in legacy research — protocols where the daily dosing pattern is specifically needed (sensitivity studies, fine-grained titration) or where Liraglutide has the longer clinical-data history that a research question demands.
For every other modern protocol, Semaglutide is structurally better. The ~7-day half-life and weekly dosing produce fewer protocol-adherence failures, and the magnitude of effect on both weight and HbA1c is roughly 50-70% larger than Liraglutide at comparable receptor saturation.
In the practitioner corpus we reference, the one consistent scenario where Liraglutide still appears: research subjects with extreme GI sensitivity who cannot tolerate the higher integrated exposure of weekly Semaglutide. The daily peak-and-trough pattern of Liraglutide is actually gentler in rare cases. This is a narrow slice of protocols.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Is Liraglutide just a weaker Semaglutide?
+
Effectively yes. Same receptor, same class, shorter half-life, smaller magnitude. Semaglutide was engineered as the improved version of Liraglutide.
Why would anyone still use Liraglutide?
+
Legacy clinical-data comparability, daily-titration sensitivity protocols, or rare GI-tolerance edge cases where the peak-and-trough pattern is easier than weekly steady state.
Can I switch from Liraglutide to Semaglutide?
+
Yes. Most practitioner protocols hold the Liraglutide dose, introduce Semaglutide at 0.25 mg weekly, run both for 1 week, then discontinue Liraglutide. Abrupt switches produce a brief appetite rebound as the daily peak clears.
Are side effects similar?
+
Same class of side effects (nausea, constipation, occasional pancreatitis signals in outliers). Magnitude tracks integrated exposure — weekly Sema at steady state produces more continuous exposure than daily Lira does across the day.
What about Tirzepatide in this conversation?
+
Tirzepatide is the dual-pathway successor — GIP + GLP-1 vs Semaglutide's GLP-1 only. See our Semaglutide vs Tirzepatide comparison for the current generational tradeoff.
Related Comparisons
GLP-1
Semaglutide vs Tirzepatide
Semaglutide is a single-pathway GLP-1 receptor agonist with ~7-day half-life. Tirzepatide is a dual GIP and GLP-1 agonist with ~5-day half-life and meaningfully larger magnitude on both weight and HbA1c endpoints. Both are weekly-administered research peptides; the tradeoff is potency vs tolerability and cost.
ReadGLP-1
Tirzepatide vs Retatrutide
Tirzepatide is a dual GIP / GLP-1 agonist with mature clinical data. Retatrutide is a triple agonist adding glucagon receptor activation, producing larger weight-loss signals in Phase 2 research but with less long-term safety data and a steeper side-effect curve.
ReadLongevity
MOTS-c vs SS-31
MOTS-c is a mitochondrial-derived peptide that signals systemically — it activates AMPK, improves insulin sensitivity, and enhances exercise capacity. SS-31 (elamipretide) is a mitochondrial-targeting peptide that binds cardiolipin on the inner mitochondrial membrane, preserving electron-transport-chain function and reducing oxidative damage. Same organelle, completely different mechanism.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.